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Abstract: Ketogenic diets are high in fat and low in carbohydrates and represent a well-established and effective treat-
ment alternative to anti-epileptic drugs. Ketogenic diets are used for the management of a variety of difficult-to-treat or in-
tractable seizure disorders, especially pediatric refractory epilepsy. However, it has been shown that this dietary therapy 
can reduce seizures in people of all ages, and ketogenic diets are being applied to other prevalent medical conditions such 
as diabetes. Although used effectively to treat epilepsy for nearly 90 years, the mechanism(s) by which ketogenic diets 
work to reduce seizures remain ill-understood. One mechanism receiving increased attention is based on findings that ke-
togenic diets increase the brain energy molecule ATP, and may also increase the levels and actions of the related endoge-
nous inhibitory neuromodulator adenosine. ATP and adenosine have both been identified as important modulators of sei-
zures; seizures increase the actions of these purines, these purines regulate epileptic activity in brain, adenosine receptor 
antagonists are pro-convulsant, and adenosinergic mechanisms have been implicated previously in the actions of approved 
anti-epileptic therapeutics. Here we will review recent literature and describe findings that shed light on mechanistic rela-
tionships between ketogenic diets and the purines ATP and adenosine. These emerging mechanisms hold great promise 
for the effective therapeutic management of epileptic seizures and other neurological conditions.  
Keywords: Adenosine, ATP, brain, epilepsy, metabolism, seizures. 
INTRODUCTION 
Epilepsy is a prevalent brain disorder characterized by a 
predisposition to generate seizures due to excessive or asyn-
chronous neuronal activity in brain [1]. The incidence of 
epilepsy is particularly high in young children ( 5 years 
old), in young adults especially those engaged in combat, 
and in those over the age of 65 [2, 3]. As a neurological dis-
order, epilepsy is poorly classified as it has multiple known 
and unknown genetic and environmental causes, manifesta-
tions, seizure types, and identifiable syndromes; an onset of 
epilepsy associated with head trauma, central nervous system 
infections, and tumors may occur at any age [3]. The inci-
dence and prevalence of epilepsy have been increasing be-
cause of combat-associated head injuries and an aging popu-
lation, and this trend is predicted to continue [4, 5]. Thus, 
new therapeutic strategies are needed, and effective interven-
tions could benefit a broad and growing population.  
Antiepileptic drugs (AEDs) are used typically and widely 
for the treatment of epilepsy. The aim of AED treatment is to 
control seizures while minimizing adverse side-effects; un-
fortunately AEDs are effective for only 60–70% of epileptic 
individuals, and undesirable side-effects are not uncommon 
[6-8]. In ancient times, epilepsy was treated through the die-
tary intervention of starvation, which forces a switch from  
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glucose-based to ketone-based metabolism. This simple but 
extreme treatment led to the hypothesis and its clinical con-
firmation that maintaining ketone-based metabolism by lim-
iting carbohydrates, while still ingesting adequate calories, 
could control seizures [9]. Currently a major alternative and 
non-pharmacological treatment for epilepsy is adhering to a 
high-fat, low-carbohydrate ketogenic diet (KD), and over 
many years its efficacy has been confirmed in retrospective, 
prospective, and multi-center studies [10-13]. Since its in-
ception, KD has been employed to maintain ketosis and con-
trol epileptic seizures primarily in children who do not re-
spond well to AEDs [14, 15].  
KETOGENIC DIETS AND EPILEPSY: APPLICA-
TIONS, BENEFITS AND LIMITATIONS 
The KD requires strict compliance to maintain anticon-
vulsant effects. It limits the consumption of carbohydrates 
persistently and sufficiently such that the carbohydrate con-
tent does not provide enough glucose to serve as an available 
energy source. Without adequate glucose, the brain is forced 
metabolically to switch from mostly glycolytic pathways to 
ketolytic mechanisms whereby ketones are produced (mainly 
in the liver) and used as the main fuel to generate ATP for 
cellular metabolism.  
The KD ratio prescribed clinically is a specific ratio of 
fat to protein plus carbohydrate. A typical KD contains the 
ratio of 4:1 (fat: protein + carbohydrates). Approximately 
90% of dietary calories are derived from fat whereas < 5% 
comes from carbohydrates [16, 17]. Proteins are added to the 
diet to meet requirements depending on the individual’s age 
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and size. In some treatment protocols, fluids and calories are 
restricted - total caloric intake is targeted to 75% of the rec-
ommendation for the individual’s age; however there is no 
evidence that forced caloric restriction or fluid restriction is 
necessary for the clinical benefit to be observed [18].  
As noted, an analogous switch to ketone-based sources of 
cellular energy occurs during fasting/starvation. Without 
imposing unhealthy fasting/starvation approaches, adherence 
to a KD can provide adequate calories and energy while pro-
tecting against generation of epileptic seizures. The diet re-
duces seizure frequency by greater than 90% for one-third of 
children on the diet and by greater than 50% for an addi-
tional one-third of children [19, 20]. It appears that a KD is 
more or less as effective in controlling seizure activity in 
adults as it is in treating children with epilepsy, but there 
have been comparatively few studies on adults [21, 22]. One 
reason why a KD is more commonly applied in and per-
ceived as successful in pediatric epilepsy is that it is easier to 
initiate, control food intake and maintain this strict diet in 
children. Most pediatric patients that respond well to the KD 
are weaned from the diet after two years because the anti-
convulsant effect achieved is often permanent [23, 24].  
Although the KD is highly effective, it does have its 
shortcomings; main criticisms include it being a diet that is 
restrictive and unpalatable. In addition, it can cause constipa-
tion, kidney stones, and, depending on the saturated fat com-
position of the diet, cardiovascular complications [25-28]. A 
low-carbohydrate diet with a healthier fat composition might 
reduce complications [29]. More research is clearly needed 
in this area to determine more accurately side effects and 
long terms consequences.  
To date, the key mechanisms underlying the success of a 
KD in reducing seizures are unclear [30, 31]. Proposed 
mechanisms include increased GABA, increased mitochon-
drial gene expression, direct effects of ketones on neurons, 
pH changes, and altered ion channels - particularly K
+
 chan-
nels. This knowledge gap has limited the use of KDs for epi-
lepsy and potentially other disorders, as well as stymied ef-
forts to develop drugs that could take advantage of the anti-
convulsant mechanisms mobilized by a KD [32]. Despite its 
efficacy, KD treatment has inherent drawbacks and limita-
tions and a better mechanistic understanding of its actions 
could lead to better diet-based approaches including those 
with fewer restrictions and complications. Importantly, an 
understanding of underlying mechanisms should result in 
new directions for basic and clinical research [33].  
Here we focus on the relationship between adhering to a 
KD and increased brain levels of ATP and adenosine as a 
new insight into epilepsy treatment. The purines ATP and 
adenosine link metabolism to neuronal activity [34], and cell 
bioenergetics may be a key regulator of seizure activity [35, 
36]. Importantly, adenosine is an endogenous anticonvulsant 
[37-39] which is effective in numerous seizure models, in-
cluding acute and chronic electroconvulsive and pharmacol-
ogical paradigms [40-44], and is also effective in pharma-
coresistant kainate-induced seizures [45-47].  
Adenosine acting at the adenosine A1 receptor (A1R) sub-
type could be the final key mechanism by which adhering to 
a KD prevents seizures [48, 49]. Although more research is 
needed, to date there are a few seizure models where both 
adenosine and a KD have been shown to be effective, includ-
ing electrical kindling of the amygdala in rats [42-44, 50], 
acute bicuculline injection [41, 51, 52], pentylenetetrazol 
kindling in mice [53-55], and the epileptogenic phase after 
kainate treatment [45-47, 56, 57]. Overall, a purine-targeting 
metabolic strategy - ultimately increasing the actions of the 
anticonvulsant molecule adenosine - has great potential to 
treat a wide variety of epileptic seizures.  
EPILEPSY AND ENERGY METABOLISM 
During seizures neurons undergo prolonged depolariza-
tion that leads to large fluxes of ions across plasma mem-
branes. As a result there is intracellular accumulation of so-
dium and calcium ions, and an increased requirement to ex-
pend large amounts of energy (mostly ATP) to re-establish 
the interior milieu. ATP is necessary to maintain resting 
membrane potentials, and depletion of intracellular ATP in 
an effort to export accumulated ions can lead to bioenergetic 
crisis and/or redox catastrophe. Sodium-potassium-ATPase 
is largely responsible for maintaining these ionic gradients 
[58]; under basal conditions it has been estimated that  
ATPase consumes 25-40% of the brain’s energy [59], and 
after seizure activity ATPase likely consumes an even 
greater percentage of brain energy to restore the resting 
membrane potential. Decreased levels of ATP can reduce the 
cell’s energy charge and its ability to maintain homeostasis 
and normal neuronal function and signaling, and, during an 
acute energy demand such as a seizure, the need for ATP 
can very readily and rapidly supersede supply. Thus, ade-
quate intracellular ATP is central to controlling cellular en-
ergy, seizure generation, and neuronal membrane polarity.  
Compared to the large and constant levels of ATP inside 
the cell, extracellular ATP is relatively insignificant and 
transient. A net dephosphorylation of ATP to ADP, AMP 
and adenosine occurs extremely rapidly (the t of ATP in the 
extracellular space is about 200 ms [60]). Together, ATP and 
its core molecule adenosine are intricately involved in main-
taining cellular energy levels and in controlling neuronal 
excitability via cell-surface receptors. Intracellular adenosine 
is especially important because it is a very sensitive measure 
of the balance between cellular energy supplies and energy 
demand. Its actions to reduce neuronal activity and energy 
demand and re-establish equity between supply and demand 
via feedback on cell-surface receptors is a concept central to 
adenosine being considered a retaliatory metabolite [61]. 
Extracellular adenosine is a powerful endogenous anticon-
vulsant, with great potential for treating all types of epileptic 
seizures. Traditionally, adenosine has been recognized as the 
brain’s own anticonvulsant molecule and a powerful en-
dogenous neuromodulator: tonic levels are present through-
out the extracellular space, it is released from cells during 
seizures, ischemia, and hypoxia [62-64], its actions can also 
be increased by stimuli such as changes in temperature and 
pH [65-70], and it may be more sensitive to these changes 
during conditions of increased excitability [71].  
Adenosine is released during seizures, and adenosine 
through its activation of high-affinity A1Rs contributes to 
termination of seizures by reducing neuronal excitability [45, 
72-74]. Activation of A1Rs pre- and postsynaptically de-
creases excitatory neurotransmitter release [75] and hyperpo-
larizes postsynaptic membrane potentials by promoting po-
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tassium conductance [76]. The brain in general and the sei-
zure-prone hippocampus in particular contain high levels of 
A1Rs. There is abundant evidence that the powerful anticon-
vulsant role of endogenous adenosine occurs through this 
receptor subtype [77-80]. For example the ictal EEG events 
of bicuculline-injected rats were suppressed by focal applica-
tion of adenosine [78] and A1R agonists suppress even 
pharmacoresistant epilepsy of kainate injected mice [45]. 
Conversely, antagonists of A1Rs are pro-convulsant [81]. 
Thus, adenosine is similar to the KD in that both are effec-
tive at reducing seizures that are refractory to other treat-
ments. Unfortunately, drug-based strategies that directly tar-
get adenosine A1Rs generally face vexing pharmacological 
obstacles including peripheral side effects such as reduced 
heart rate and blood pressure [82]. More recently, localized 
adenosine based-therapies show significant promise but are 
necessarily invasive and best suited to well-localized, focal 
seizures [80, 83].  
Extracellular ATP is a major source of extracellular 
adenosine [84, 85], and, as noted, is metabolized rapidly to 
adenosine [60]; these enzymatic reactions are catalyzed by a 
variety of ecto-ATPases and 5’-nucleotidases [60]. Thus, 
increased levels of either purine in seizure-prone brain areas 
containing A1Rs could help to either prevent or to terminate 
seizures. At this time it is neither well-understood how a KD 
differentially affects purinergic mechanisms and metabolism 
in various cell types in the central nervous system, nor has it 
been determined what roles different cell types might play in 
a KD’s anticonvulsant benefits. Nevertheless, it has been 
established that ATP and adenosine in the central nervous 
system can originate from neurons themselves as well as 
from other cell types, most notably from astrocytes. Astro-
cytes are abundant, and particularly complex in humans [86, 
87], and purines released from astrocytes influence synaptic 
transmission. Astrocytes release ATP through hemichannels 
as well as from neurosecretory vesicles; extracellular adeno-
sine derived from astrocytic ATP influences neuronal excit-
ability, plasticity, and sleep [88-90]. However, astrocyte in-
volvement in the relationship between purines and epilepsy 
is complicated by findings that astrogliosis occurs in epi-
lepsy and brain injury, astrocytes transport adenosine into 
the cell interior, adenosine kinase very actively catalyzes the 
phosphorylation of adenosine to AMP within astrocytes, and 
increased levels of adenosine kinase decreases the extracellu-
lar levels and actions (including anticonvulsant actions) of 
adenosine [91].  
PURINES AND THE KETOGENIC DIET 
Many hypotheses have been advanced and tested in on-
going attempts to determine mechanisms responsible for the 
antiepileptic effects of a KD. Acidosis, dehydration and ke-
tosis were the first mechanisms to be considered when the 
KD was first introduced as a metabolic strategy which could 
mimic fasting-induced seizure protection [15]. None of these 
initial mechanisms appeared sufficient to explain clinical 
observations, and subsequently, investigators attributed the 
protective actions of a KD to alterations in levels of neuro-
transmitters (including GABA, norepinephrine and gluta-
mate), glucose restriction, activation of ATP-sensitive K
+
 
channels, circulating factors including polyunsaturated fatty 
acids and their downstream effectors, decreased neuronal 
excitability, transformations of cerebral energy metabolism 
and increased purines [15, 30, 48]. Identifying critical anti-
convulsant mechanisms underlying the success of KD ther-
apy remains a topic of intense research, and changes in gene 
expression, altered energy metabolism, and changes in the 
levels and actions of purines are very strong candidates [48, 
49, 92-94].  
For over 30 years it has been recognized that KD can 
lead to increased levels of ATP in brain [92] and it also in-
creases the ratio of phosphocreatine to ATP [95]. More re-
cently we used methods able to provide precise and accurate 
measures of brain energy metabolites in brain and reported 
that rats fed a calorie-restricted KD for three weeks had in-
creased ratios of phosphocreatine to creatine in hippocampus 
[94]; such increases suggest that alternative sources of high 
energy phosphate are available and might thereby protect 
against ATP utilization and depletion. Subsequently, we 
showed that KD increased levels of ATP in brains of KD-fed 
animals.
1
  
Some clinical reports suggest that a KD can offer seizure 
protection promptly [96, 97], and some research shows that 
acute ketone treatment can be directly anticonvulsant [98]. 
At least two reports show that ketones or an in vitro ana-
logue of ketogenic metabolism increases hyperpolarization 
via postsynaptic ATP-sensitive K
+
 channels [99, 100]. How-
ever, many reports note that a KD can take several days or 
weeks before becoming maximally effective [eg. 101]. Ac-
cordingly, it was hypothesized that this delay was due to 
alterations in gene expression generally and more specifi-
cally due to alterations in genes involved in the control of 
energy metabolism [94]. Using gene microarray technology, 
normal 37-41 day old rats placed on a KD for 21 days were 
found to have upregulated genes for oxidative phosphoryla-
tion. In agreement with this, mitochondrial biogenesis was 
increased, and, as noted above, brain levels of phos-
phocreatine relative to creatine were increased [94]. Thus, 
improved brain bioenergetic status might play an important 
role in the anti-seizure effects of KD.  
Measured increases in cell bioenergetics in conjunction 
with the gene array data suggest strongly that brain energy 
metabolism in general and purines in particular might be 
mechanisms central to the therapeutic effects of the KD. In-
creasingly, recent research and proposed hypotheses about 
the KD suggest that higher levels of both ATP and adenosine 
underlie some of the anticonvulsant success as well as 
emerging applications for a KD and analogous ketogenic 
metabolic strategies [33, 48, 49, 100]. Augmenting extracel-
lular adenosine offers both pre- and postsynaptic inhibitory 
mechanisms as well as established clinical potential beyond 
epilepsy including brain injury, pain and sleep disorders [33, 
88]. Furthermore, understanding the mechanisms underlying 
the success of KD for epilepsy would be a major break-
through, as this metabolism-based therapy can alleviate sei-
zures even in cases of intractable epilepsy.  
Clinical observations that a KD can be effective in intrac-
table epilepsy suggest that although the spectrum of mecha-
nisms underlying the success of KD therapy could overlap, 
they must be distinct from those targeted primarily by AEDs. 
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Research in animal models is very clear that adenosine is a 
powerful global and local seizure-suppressor, and an adeno-
sine or A1R deficiency alone is sufficient to trigger seizure 
activity [47, 102]. To date, a variety of adenosinergic 
mechanisms have been implicated in the actions of AEDs 
including AEDs interacting with A1Rs and increasing their 
anti-epileptic effectiveness, and AEDs binding to A1Rs di-
rectly [103-105]. When considering all of the intra- and ex-
tracellular regulatory mechanisms for controlling the levels 
and actions of purines in brain, and the respective contribu-
tions of neurons and astrocytes, the greatest net benefit of the 
anticonvulsant effects of purines would be achieved by 1) 
maintaining overall cell energy levels, 2) at least maintaining 
(if not increasing) cellular levels of ATP, and 3) increasing 
levels of extracellular adenosine, either directly or as a con-
sequence of increased extracellular ATP and its dephos-
phorylation to adenosine.  
In addition to evidence that a KD in vivo may change 
ATP and adenosine, increases in these purines have been 
implicated in cellular consequences of ketogenic metabolism 
both in vitro and in vivo. For example, moderate hypoglyce-
mia or glycolytic inhibition can both increase adenosine 
[106-108] and offer anticonvulsant benefits [109, 110]. Re-
cent electrophysiological evidence shows that sufficient or 
high intracellular ATP and lowered extracellular glucose 
mobilizes an autocrine inhibition via A1Rs [100]. Diverse 
findings that a KD or ketogenic metabolic strategies work 
through purines, and particularly through adenosine, does 
not negate or eliminate other metabolic changes precipitated 
by this metabolic switch. Rather, these findings may help 
simultaneously pinpoint specific and critical mechanisms 
and identify a new strategy for adenosine regulation, opening 
new avenues for the treatment of seizure disorders and a 
broad array of other diseases.  
SUMMARY 
Traditionally, the KD is used mainly in children. While it 
has limitations, KD therapy may be more effective in the 
management of childhood seizures than currently available 
AEDs [111], and can offer permanent benefits [112]. The 
KD might also slow the progression of this disorder and thus 
be antiepileptogenic [56, 113]. Certainly more research is 
needed in this area. Unfortunately, until the mechanism(s) by 
which the KD provides protection are better delineated, this 
knowledge gap makes is difficult to fashion an even better 
and more widely accessible therapeutic approach. Neverthe-
less, with respect to the relationship among KDs and purines, 
a better insight into how this metabolic switch influences 
purines could yield new approaches to purine-based thera-
pies which have shown potential for treating a diverse array 
of acute and chronic conditions. 
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